Plasmodium falciparum sporozoite and liver stage antigens

Patent metadata

Field	Value
Publication number	US-9694062-B2
Application number	US-201414219390-A
Country	US
Kind code	B2
Filing date	Mar 19, 2014
Priority date	Nov 5, 2009
Publication date	Jul 4, 2017
Grant date	Jul 4, 2017

Abstract

The invention provides novel malaria polypeptides expressed at the pre-erythrocytic stage of the malaria life-cycle. The antigens can be utilized to induce an immune response against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in DNA or other nucleic acid expression systems delivered as a vaccine formulation.

First claim

What is claimed is:

1. An immunogenic composition comprising a vector expression system, wherein said vector comprises nucleic acid sequences encoding separate polypeptides wherein the separate polypeptides comprise a polypeptide with the amino acid sequence of SEQ ID NOs: 6 and a polypeptide comprising the amino acid sequence of SEQ ID NO. 10, wherein said suitable vector expression system is a DNA plasmid or replicating or nonreplicating viral vector.

2. The immunogenic composition of claim 1 , wherein said separate polypeptides are encoded by the nucleic acid sequences of SEQ ID NOs. 5 or 9 inserted into said suitable vector expression system.

3. A method of inducing an immune response against malaria in a mammal, which method comprises administering the immunogenic composition of claim 1 .

4. The method of claim 3 , wherein of said isolated polypeptides are encoded by the nucleic acid sequences of SEQ ID NOs. 5, or 9.

5. The method of claim 3 , wherein said method further comprises administering to said mammal one or more priming and one or more boosting immunizations, wherein said priming and boosting immunizations of an immunologically effective amount of said polypeptides of claim 1 expressed by a suitable plasmid or replicating or nonreplicating viral vector.

6. The method of claim 5 , wherein said suitable expression vector is selected from the group consisting of DNA plasmid, alphavirus replicon, adenovirus, poxvirus, adenoassociated virus, cytomegalovirus, canine distemper virus, yellow fever virus, retrovirus, RNA replicons, DNA replicons, alpha virus replicon particles, Venzuelean Equine Encephalitis Virus, Semliki Forest Virus and Sindbus Virus.

7. The method of claim 6 , wherein the poxvirus is selected from the group consisting of cowpox, canarypox, vaccinia, modified vaccinia Ankara, or fowlpox.

8. The immunogenic composition of claim 1 , wherein said vector expression system also comprises nucleic acid sequence of SEQ ID NO. 13 encoding the polypeptide with the amino acid sequence of SEQ ID NO. 14.

9. The immunogenic composition of claim 1 or claim 8 , wherein said vector expression system also comprises nucleic acid sequence encoding one or more of the polypeptides with the amino acid sequences selected from the group consisting of SEQ ID NOs: 2, 4, 8, and 12.

10. The immunogenic composition of claim 9 , wherein said nucleic acid sequences are selected from the group consisting of SEQ ID NOs: 1, 3, 7, and 13.

11. The method of claim 3 , wherein said composition also comprises nucleic acid sequences encoding one or more of the polypeptides with the amino acid sequence selected from the group consisting of SEQ ID NOs. 2, 4, 8, 12 and 14.

12. The method of claim 11 , wherein said nucleic acid sequences are selected from the group consisting of SEQ ID NOs. 1, 3, 7 and 13.

Assignees

• Aguiar Joao
• Limbach Keith
• Sedegah Martha
• Richie Thomas
• Us Navy

Inventors

• Aguiar Joao
• Limbach Keith
• Sedegah Martha
• Richie Thomas

Classifications

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61K2039/53

  DNA (RNA) vaccination · CPC title

• A61K39/015 Primary

  Hemosporidia antigens, e.g. Plasmodium antigens · CPC title

• A61P33/06

  Antimalarials · CPC title

• A61P37/04

  Immunostimulants · CPC title